Hillsdale Investment Management Inc. Grows Stake in Johnson & Johnson $JNJ

Hillsdale Investment Management Inc. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1,942.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 44,762 shares of the company’s stock after purchasing an additional 42,570 shares during the period. Hillsdale Investment Management Inc.’s holdings in Johnson & Johnson were worth $6,837,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Brighton Jones LLC boosted its position in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after purchasing an additional 6,332 shares during the period. Wealth Group Ltd. bought a new position in Johnson & Johnson in the 1st quarter worth approximately $218,000. Smart Money Group LLC grew its stake in Johnson & Johnson by 6.5% in the 1st quarter. Smart Money Group LLC now owns 6,687 shares of the company’s stock valued at $1,109,000 after buying an additional 407 shares in the last quarter. GW&K Investment Management LLC raised its holdings in Johnson & Johnson by 4.7% during the 1st quarter. GW&K Investment Management LLC now owns 3,075 shares of the company’s stock valued at $510,000 after acquiring an additional 137 shares during the period. Finally, United Bank lifted its position in shares of Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after acquiring an additional 4,876 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on JNJ shares. Daiwa Capital Markets upgraded Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price target for the company in a research report on Monday, October 20th. Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Argus set a $210.00 price target on Johnson & Johnson in a research report on Wednesday, October 15th. Scotiabank initiated coverage on shares of Johnson & Johnson in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 price target on the stock. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $209.00 price objective on shares of Johnson & Johnson in a research note on Friday, October 10th. Four analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $201.05.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Up 0.4%

JNJ stock opened at $203.29 on Friday. The company’s 50 day moving average is $187.74 and its 200 day moving average is $171.22. The stock has a market cap of $489.77 billion, a price-to-earnings ratio of 19.62, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $204.51.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.